Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 7290 in Adult Participants With ADHD
NCT07755410Phase 2Recruiting
- Sponsor
- Alkermes
- Start
- Aug 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ALKS 7290 in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by Alkermes. Primary endpoint: Attention Deficit Disorder Investigator Symptom Rating Scale at 4 weeks. Started Aug 2026; status: recruiting.
02
Drugs
ALKS 7290
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07755410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07755410.